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Background: Late prognosis of Community-Acquired Pneumonia (CAP) patients is related to cardiovascular events.
Persistence of inflammation-related markers, defined by high circulatory levels of interleukin 6 and 10 (IL-6/IL-10),
is associated with a higher post-event mortality rate for CAP patients. However, association between these markers
and other components of the immune response, and the risk of cardiovascular events, has not been adequately
explored. The main objectives of this study are: 1) to quantify the incidence of cardiovascular disease, in the year
post-dating their hospital admittance due to CAP and, 2) to describe the distribution patterns of a wide spectrum
of inflammatory markers upon admittance to and release from hospital, and to determine their relationship with
the incidence of cardiovascular disease.
Methods/design: A cohort prospective study. All patients diagnosed and hospitalized with CAP will be candidates
for inclusion. The study will take place in the Universitary Hospital La Princesa, Spain, during two years. Two samples
of blood will be taken from each patient: the first upon admittance and the second one prior to release, in order to
analyse various immune agents. The main determinants are: pro-adrenomedullin, copeptin, IL-1, IL-6, TNF-α, IL-17,
IFN-γ, IL-10 and TGF-β, E-Selectin, ICAM-1, VCAM-1 and subpopulations of peripheral T lymphocytes (T regulator,
Th1 and Th17), together with other clinical and analytical variables. Follow up will start at admittance and finish a
year after discharge, registering incidence of death and cardiovascular events. The main objective is to establish
the predictive power of different inflammatory markers in the prognosis of CAP, in the short and long term, and their
relationship with cardiovascular disease.
Discussion: The level of some inflammatory markers (IL-6/IL-10) has been proposed as a means to differentiate the
degree of severity of CAP, but their association with cardiovascular risk is not well established. In this study we aim
to define new inflammatory markers associated with cardiovascular disease that could be helpful for the prognosis
of CAP patients, by describing the distribution of a wide spectrum of inflammatory mediators and analyzing their
association with the incidence of cardiovascular disease and mortality one year after release from hospital.
Keywords: Community-acquired pneumonia (CAP), Cardiovascular events, Inflammatory markers, CAP late mortality* Correspondence: jaspa@separ.es
1Servicio de Neumología, Hospital Universitario de la Princesa, Instituto de
Investigación Sanitaria Hospital Universitario de la Princesa, IP, Madrid,
España
Full list of author information is available at the end of the article
© 2014 Rajas et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Rajas et al. BMC Pulmonary Medicine 2014, 14:197 Page 2 of 8
http://www.biomedcentral.com/1471-2466/14/197Background
Community acquired pneumonia (CAP) is an important
worldwide health problem. It is the most frequent infec-
tious disease requiring hospitalization. The Incidence of
CAP in Europe ranges from 1.2 to 11.6 cases per 1000
of population per year, with rates of hospitalization ran-
ging from 40 to 60% [1,2].
The mortality rate of CAP during hospitalization is
well known. But various authors have reported an in-
creased mortality rate after a long-term follow-up of
hospitalized, Community-Acquired Pneumonia (CAP)
patients who survived the illness. It has even been ob-
served after allowing for age and co-morbidity. This ten-
dency has been related to the Pneumonia Severity Index
(PSI) risk scale [3-9].
It is known that significant cardiac complications are
produced in a large proportion of CAP patients [10-13],
with a greater incidence at the outset of the event, but
also during its evolution and follow-up. Perry et al. [14],
in connection with a very broad sample (50,119 sub-
jects), recently published that a significant number of
patients, with follow-up during 90 days after admittance
for CAP, experienced a cardiovascular event, principally
during hospitalization, with a rate of 1.5% for myocardial
infarction, 10.2% for congestive heart failure, 9.5% for
arrhythmia, 0.8% for unstable angina and 0.2% for ictus.
Other authors previously had already described this rela-
tionship [15,16].
Likewise Jasti et al. [17] described how the majority of
readmissions after CAP resulted from cardio-pulmonary
or underlying neurological diseases. Corrales-Medina
et al. [18] also described the association between acute
bacterial pneumonia and acute coronary syndrome. Be-
sides, the relationship between coagulation disorders
and CAP has also been reported [19].
Epidemiological data have shown a strong relationship
between acute respiratory infections and a later myocar-
dial infarction [20,21]. Furthermore, it is known that
chronic inflammation destabilizes atheroma plaque and
induces a pro-coagulant state [22]. Very recently it has
been described that an important number of patients have
new cardiac arrhythmia during and post-hospitalization
for pneumonia [23].
Altogether these observations suggest that the way of
regarding CAP should be changed: early diagnosis, bet-
ter monitoring, and risk stratification in CAP with re-
spect to cardiovascular diseases should be established.
A growing interest has developed in identifying dif-
ferent biological markers suitable for establishing a cor-
rect diagnosis and adequately evaluating the severity
and prognosis of the disease [24-27]. Various candidate
biomarkers have been studied, including inflammatory
molecules such as C-reactive protein, IL-6, IL-1 and
procalcitonin and also cardiovascular biomarkers suchas proatrial natriuretic peptide (pro-ANP), proarginin-
vasopresin (copeptin), proendothelin-1 and Mid-regional
pro-adrenomedullin (MR-Pro-ADM). These cardiovascu-
lar biomarkers are good predictors, both in the short and
in the long term, for the prognosis of CAP [26]. In a refer-
ence study, MR-pro-ADM resulted to be the most useful
biomarker [25]. Moreover, it also was an excellent marker
to predict short and long term mortality in CAP, regard-
less of its etiology [28].
It has been reported that persistent high circulatory
levels of IL-6 and IL-10 after CAP are associated with an
increased mortality in the follow-up [29,30], pointing to a
relationship between a persistent inflammation upon re-
lease from hospital and the long-term prognosis. More-
over, in apparently healthy subjects, high levels of IL-6 are
related with a greater risk of myocardial infarction in the
future [31]. It remains to be established whether these in-
flammatory mediators could be used as biomarkers for
prognosis of cardiovascular risk in CAP patients.
Immune response is very complex and many other
molecules might be used as biomarkers. Of great rele-
vance in the long-term inflammatory response against
infectious agents is the generation of the T lymphocyte
effectors type Th1 and Th17, which are capable of medi-
ating the inflammatory response by means of their cyto-
kine effectors IFN-γ and IL-17 in response to such
infectious agents [32,33]. Likewise, the unregulated ac-
tion of these cellular populations is involved in numer-
ous autoimmune inflammatory processes [34,35]. The
inflammatory state is negatively regulated by factors
such as anti-inflammatory cytokines like IL-10 (already
studied in CAP) and TGF-β [36] and by T regulator
lymphocytes (Treg). The Treg cell populations, charac-
terized by the expression of certain markers such as the
transcription factor FoxP3, are capable of attenuating
the inflammatory response mediated by T cells in
numerous pathological processes [37]. The balance be-
tween all these pro and anti-inflammatory factors deter-
mines the inflammatory state of the organism. During
inflammatory processes the activation of the vascular
endothelium increases the expression of inducible
leukocyte adhesion molecules such as ICAM-1, VCAM-
1 and E-selectin which mediate the adhesion and ex-
travasation of leukocytes to the inflammation site [38].
During the inflammatory process which affects the
endothelial barrier, an increase in the soluble forms of
these molecules liberated to the extracellular medium is
produced in such a way that their circulatory levels may
be indicators of inflammatory processes related with car-
diovascular risk [39]. All these mediators of immune re-
sponse could be considered as candidate biomarkers to
evaluate cardiovascular risk and prognosis in CAP.
The current research project intends to quantify the
incidence and mortality of cardiovascular disease in
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to CAP.
Moreover, this project tries to describe a wide spectrum
of immune response mediators upon admission to and re-
lease from hospital in CAP patients. Many of these media-
tors have been already studied in CAP but some others
will be analyzed for the first time.
Our aim is to establish a profile of the inflammatory
state of these patients and determine its possible rela-
tionship with the incidence of cardiovascular disease.
Methods/design
A cohort prospective study to determine the prognosis
and the incidence of cardiovascular events after admis-
sion to hospital due to a CAP episode and the predictive
value of a wide panel of biological inflammatory
markers. All the patients will be followed up on for at
least one year after discharge and every new cardiovas-
cular event will be recorded. The study will take place
in the University Hospital “La Princesa” (HUP), a refer-
ence center for emergencies and admissions for three
hundred thousand inhabitants in the Northeastern area
of Madrid (Spain).
Candidates for this study will be all those patients
who are attended to and are subsequently admitted to
the hospital due to CAP between 01/01/2014 and 31/
12/2015. They must satisfy the following conditions: be
older than 18, show symptoms of lower airway infec-
tion, together with the existence of fresh radiological
infiltrate, and be then diagnosed with pneumonia and
subsequently admitted. There must be no alternative
diagnoses during follow-up, and the subjects must not
have been hospitalized in at least the ten days preced-
ing the current episode. Signed informed consent will
be required. The exclusion criteria will concern those
patients who are unreachable during the follow-up
time.
The Clinical Research Ethics Coimmittee of the hospital
has approved this study.
Main outcomes or primary outcome
The dependent variable in this study is the development
of cardiovascular disease according to the following clin-
ical criteria: pacemaker emplacement, acute myocardial
infarction, heart failure, acute pulmonary edema, unstable
angina, ictus, transitory ischemic cerebral affectation, pul-
monary thrombo-embolism and deep venous thrombosis.
Moreover, mortality from cardiovascular diseases or any
other cause will be registered. These events will be col-
lated during the episode of CAP and during follow-up
over one year. Furthermore, the follow-up point at which
a cardiovascular event diagnosis or death occurs will be
collated with the aim of estimating the incidence in terms
of incident density.Independent variables
Upon admittance to the emergency department: age,
gender, previous antibiotic treatment (type, days, and
dosage), vaccination condition (flu and pneumococcal)
will be registered as independent variables. In addition,
current treatment, especially in relation with cardiovas-
cular disease - antiaggregants, oral anticoagulants, beta-
blockers, calcium-antagonists, ACE inhibitors, Angiotensin
II receptor blockers, Direct renin inhibitor, mineralo-
corticoid receptor antagonist, anti-arrhythmics, insulin,
oral hypoglucemiants, fibrates, niacin, omega three, fit
sterols – will also be recorded.
Co-morbidities
Smoking status (packs per year), alcohol consumption,
Charlson index [40], peripheral arterial disease (symptom-
atic or asymptomatic), previous stroke (established or
transient ischemic attack), diabetes, obesity, high blood
pressure, dyslipemia, chronic kidney disease (glomerular
filtration rate –GFR- < 60 ml/m and/or increased high
fractional excretion of albumin), liver disease, HIV in-
fection, neoplasic disease, collagen disease, ischemic cardi-
opathy (MI or revascularization), previous pulmonary
thromboembolism or deep venous thrombosis, ICU ad-
mission, prior pneumonia and cardiovascular risk evalu-
ation in accordance with the score [41] will all be taken
into consideration.
During hospitalization
CURB-65 [42], PSI [43], sepsis, septic shock, pleural ef-
fusion, empyema, multilobar impairment, hospital stay,
admittance to ICU, need for assisted ventilation, micro-
biological results.
Analytical parameters
Peripheral blood samples will be taken on admittance
and near to discharge. The time of the second sample
corresponding to release has been standardized to being
between the third and the fifth day after the admittance
of the patient in order to avoid sample acquisition losses
for the project (see Figure 1). This decision was taken
based on the effects of the treatment administered to
the patient and its repercussions on the inflammatory
markers.
In both samples the following will be determinated: chol-
esterol levels (LDL, HDL), triglycerides, glucose, HbA1c,
creatinine, urea, GFR, ions, blood cell counts, c reactive
protein, erythrocyte sedimentation, fibrinogen and coagu-
lation. Besides these, several biological markers will be ana-
lyzed (see below).
Biological markers
One part of the blood sample will be processed to obtain








Inflammatory markers at admittance
Inflammatory markers at hospital discharge
or prior to death
Figure 1 Flow chart of the study. *CAP: community adquired
pneumonia. **Hospital visit or telephone contact.
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sample will be used to analyze, by flow cytometry, the
sub-populations of the T, Th1, Th17 and T regulator
lymphocytes.
1. Soluble Mediator Study: pro-adrenomedullin and
copeptin. pro-inflammatory cytokines: IL-1, IL-6,
TNF-α, IL-17, IFN-γ. Anti-inflammatory cytokines:
IL-10 and TGF-β. Soluble endothelial adhesion mole-
cules: E-Selectin, ICAM-1 and VCAM-1.
Determination of the levels of these soluble molecules
will be carried out using the commercially available
kit BD CBA Cytometric Bead Array (CBA) Human
Soluble Protein Flex Set. This allows the simultaneous
quantification, by flow cytometry, of multiple proteins
at a very low concentration (10–2500 pg/mL) in serum
samples. Flow cytometry will be carried out with a
FACs (Fluorescence-activated cell sorting) CANTO
cytometer and FCAPArray™ Software will be used for
the analysis and quantifications. Due to the technical
limitations of the trial, the quantification of soluble
serum factors will be carried out in batches of 90
stored serum samples.
2. Sub-populations of T Lymphocytes: by using flow
cytometry on peripheral blood lymphocytes to detect
CD4, the intracellular transcription factor FoxP3,
intracellular cytokine IFN-γ and intracellular cytokine
IL-17 will be determined. The proportion of T regula-
tory lymphocytes will be defined as the percentage
of lymphocytes CD4 + FoxP3+. The proportion of
type Th1 T-lymphocytes in peripheral blood will be
determined by the proportion of lymphocytes CD4+
IFN-γ+. The proportion of Th17 T-lymphocytes willbe defined by the proportion of lymphocytes CD4 +
IL-17 + .
For the intracellular biomarkers IL-17 and FoxP3
the use of a human Th17/Treg phenotyping kit
(BD Human Th17-Treg Phenotyping Kit) has been
chosen with the addition of an Anti-Human IFN-γ.
Before marking, stimulation of PBMC (Peripheral
Blood Mononuclear Cell) by means of PMA (Phorbol
12-myristate 13-acetate), Ionomycin and GolgiStop™,
fixation and permeabilization with specific buffers
for FoxP3 and marking using a cocktail of FoxP3,
IL-17, IFN-γ and CD4 antibodies will be performed.
Its interpretation will be carried out through a FACs
CALIBUR cytometer and its analysis by means of the
CellQuest Pro program.
Follow-up after discharge
There will be at least three visits during follow-up: at one
month, at three months and at one year (see Figure 1). If
the patient does not attend, a follow-up will be carried out
by telephone to determine the cause of absence and a
questionnaire will be completed after consultation with
the relevant primary care doctor. If the patient is admitted
to the center, suffers a cardiovascular event or dies, the
pertinent information will be recorded according to pri-
mary outcome.
Data collection method
An electronic, data-collection log, integrated into the
hospital’s clinical background system, has been specific-
ally developed for the purposes of this study. The demo-
graphic and attendance record information in the
study’s data base will be obtained from the general in-
formation system to avoid duplication. Access to the
data collection log will be restricted, by means of user
ID and password, to the study’s researchers, and with its




Assuming a cumulative cardiovascular event incidence
rate of 20% for the first year after hospital release, in
order to carry out such an estimate with a confidence
interval (CI) of 95% and with an accuracy of 5%, 243 pa-
tients would be necessary. Nevertheless, since anteced-
ents for other similar studies could not be found, and,
taking into account that relationships with molecules
not previously studied are going to be tested, it has been
decided that a sample as large as the recruitment time
period permits (2 years) will be used, thus also allowing
the possible seasonal effect to be controlled. An approxi-
mate average of 600 patients per year are attended to in
the Emergency Department with a CAP diagnosis, of
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ing to the records of the centre. Under these circum-
stances, and allowing for exclusions, it is estimated that
it will be possible to comply with the stated objectives
within the set timescale. Furthermore, in order to avoid
unnecessary work, 2 intermediate sequential analyses
will be carried out when at least 50% of the estimated
sample have completed their first year of follow-up so
that the estimated value for each molecule may be
known before the end of the study. An annual cut-off
point will be established for the evaluation of results,
potential adverse effects and possible publications.
Statistical analysis
Descriptive analysis will be carried out by quantitative
variables which will be described by their measures of
central tendency (mean) and dispersion (standard devi-
ation); qualitative variables will be described by their
proportion and standard error. Univariate and multivari-
ate logistic regression will be used to analyze the associ-
ation between the independent variables and cumulative
incidence. Also odds ratios, standard errors and the cor-
responding test hypothesis will be estimated. The ana-
lysis of the association between the qualitative variables
will be carried out using the chi-square test or Fisher's
exact test and comparing the means of different quanti-
tative variables between subgroups will be performed
using t-test or ANOVA, or their nonparametric equiva-
lent (Mann-Whiney or Kruskal-Wallis).
The dependent variables will also be analyzed with re-
spect to time: firstly by estimating their incidence dens-
ity and risk functions according to the Kaplan-Meier
method with an appropriate hypothesis test (log-rank,
Breslow, Tarone or others), and secondly by using Cox
regression models after checking proportionality risk
hypotheses. In all cases model construction will be done
according to the principle of parsimony in order to
include a limited number of variables. All values of p <
0.05 will be considered to be statistically significant. In
selection processes p <0.10 or p < 0.15 will be used as a
threshold value. Statistical analysis will be carried out
using the program Stata v12.0 in the Methodology Unit
of the Princesa Research Institute.
Discussion
The importance of CAP as a serious health problem, its
high cost in terms of morbidity and mortality and its spe-
cial relationship with the elderly, are widely-recognized
clinical facts. Patients hospitalized with a CAP diagnosis
display, after admittance, a higher mortality than patients
of their same age and degree of co-morbidity, and also
show a higher incidence of cardiovascular disease, both in
the long and the short term. Thus, new CAP prognosis
scores, which take the appearance of cardiovascular eventsinto account, have been proposed [44,45]. Various studies
dealing with the handling of CAP with the help of several
biomarkers have also been published [46-48]. Likewise,
articles that try to differentiate between the degree of
severity of CAP (severe or non-severe) according to the
measurable activity of inflammatory markers [49-51], or
help to improve patient stratification in accordance with
their levels of inflammatory cytokines, have been published
[29]. The inflammatory response to infection produced in
patients with CAP could be the cause of cardiovascular
complications modifying the prognosis of the disease [10].
Therefore, studying inflammation markers could help to
monitor cardiovascular risk and prognosis in CAP
patients.
Pneumonia is an exuberant sequestration of peripheral
neutrophils in the lungs, which is tightly regulated by
cascades of cytokines produced by the immune system in
response to an invading pathogen [52,53]. In an ideal
scenario, the acute lung inflammation is protective and
self-limiting, and once the infection has been controlled,
cytokines also function in restoring homeostasis, including
the modulation of neutrophil apoptosis. On the other
hand, a cytokine storm results in a deleterious inflamma-
tion and poor clinical outcome [53]. The contribution of
cytokines to systemic inflammatory response, together with
plaque instability, sympathetic activation, a pro-coagulatory
state and endothelial dysfunction, could lead to myocardial
damage, arrhythmia and heart failure [10].
In the current research project we aim to study the dis-
tribution, in these patients, of a wide spectrum of immune
response mediators upon admittance to and release from
hospital and establish their possible relationship with the
incidence of cardiovascular disease, and mortality. This
will permit the establishment of a profile of the inflamma-
tory state of these patients and determine its association
with cardiovascular risk.
Although the exact role of each immune mediator in
the inflammatory response during pneumonia is still a
subject of ongoing research, it is clear that different
inflammatory patterns are elicited by microorganisms [54].
In the present study we plan to analyze a panel of
immune/inflammatory mediators that include: pro-
inflammatory cytokines (IL-1, IL-6, TNF-α, IL-17, IFN-γ),
anti-inflammatory cytokines (IL-10 and TGF-β); soluble
endothelial adhesion molecules (E-Selectin, ICAM-1 and
VCAM-1) and Th1, Th17 and Treg lymphocytes. Al-
though they are grouped in this way, the classification of
cytokines as pro- and anti-inflammatory is not abso-
lute, since many cytokines are capable of exerting both
effects depending on a variety of factors [53,55,56], and
some patterns of cytokine response could best be
described based on their concentrations as high, medium
and low, rather than their pro-or anti-inflammatory
activities [57]. In addition to cytokines, we will study
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adhesion molecules, Th1 and Th17 effector lymphocytes and
T regulatory lymphocytes not tested previously in CAP. This
set of mediators covers a wide range of processes regulating
immune response and inflammation. Their analysis will help
to characterize an accurate inflammatory profile of CAP
patients and identify candidate inflammatory markers of
cardiovascular risk in CAP.
The time during follow-up at which samples for the
determination of inflammatory mediators should be taken
is an important point for this work. At which time point
would determinations better predict cardiovascular risk
and evolution/outcome? The average lifespan of the
markers needs to be considered. Many cytokines involved
in this process have a short half-life and they could be
reduced shortly after the induction of the inflammatory
response to almost undetectable levels. Accordingly, mean
cytokine concentrations are generally highest on admis-
sion and they decline rapidly over the first few days.
Therefore, measurements of blood samples taken at the
time of admission might allow us to better assess the risk
for a CAP episode. However, whereas a persistent, up-
regulated, pro-inflammatory response is associated with
deaths due to cardiovascular disease, renal failure, infec-
tion, and cancer, persistent low-grade inflammation and
immune suppression may play an important role in coron-
ary events, cerebral-vascular events, and repeat bouts of
CAP [31,53,58-61]. Therefore, when measured at the end
of hospitalization, rather than on admission cytokine levels
might actually be more predictive of adverse outcomes
after hospitalization. In the current study, blood samples
for the determination of inflammatory markers will be
taken at both time points. In this way we will be able to
establish the best time point for each marker.
In this study we aim at describing the distribution of a
wide spectrum of inflammatory markers upon the
admittance to and release from hospital of CAP patients,
and analyze their association with the incidence of
cardiovascular disease and mortality one year after release
from hospital. In this way new inflammatory markers
associated with cardiovascular disease in these patients
may be defined. These new markers could be helpful for
prognosis. The development of predictive models provides
crucial evidence for the transference of laboratory findings
to human beings and from clinical research to clinical
practice. The possibility of precisely personalizing health-
care interventions seems to be related with the amount of
combined factors in forecasting models [62].Abbreviations
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